	Procarta Biosystems, a biotech company based in the United Kingdom, has received an award from global non-profit partnership, CARB-X, potentially worth $9.2 million, to be used for the development of antibiotic precision medicines.

	In a Sep. 17, 2019 press release, the UK-based biotech revealed that it will be granted an initial non-dilutive funding of $2.2 million through the CARB-X award and with the opportunity of gaining a further $7 million should certain milestones be met. Procarta will use the money to advance its proprietary oligonucleotide-based antimicrobial platform and will specifically target infections caused by Gram-negative ESKAPE (

	“This new award from CARB-X recognizes the value of the novel modalities in our pipeline and their potential to precipitate a paradigm shift in antimicrobial treatments,” said Andrew Lightfoot, chief executive officer of Procarta in a press release. “We are delighted to have support from CARB-X recognizing the importance of developing new antibiotics to combat antimicrobial resistance.” 

	“This award from CARB-X follows closely on a €1.5-million (US$1.7-million) investment from the Novo Holdings REPAIR Impact Fund. Together, these new funds will be used to progress our lead asset, PRO-202, and to develop our proprietary drug discovery platform to build a pipeline of antimicrobial agents to cover the ESKAPE pathogens,” Lightfoot added.

Deals, Development and Manufacturing

Development

Dosage Forms

Industry News

PharmTech Europe News

PharmTech News

Supplier News

Vaccines

Procarta Biosystems has received an award from CARB-X, potentially worth $9.2 million, for the development of antibiotic precision medicines.
